Risk-adapted therapy in essential thrombocythemia and polycythemia vera

Blood Reviews

Volumn 19, Issue 5, 2005, Pages 243-252

  Finazzi, Guido ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; Hydroxyurea; Polycythemia vera; Risk factors; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; CYTOTOXIC AGENT; HYDROXYUREA; IMATINIB; IMMUNOSUPPRESSIVE AGENT; PHOSPHORUS; PIPOBROMAN;

ACUTE LEUKEMIA; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CHROMOSOME DELETION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE COURSE; EXPERIENCE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; INCIDENCE; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MYELOFIBROSIS; NEUROLOGIC DISEASE; PATIENT; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN CARCINOMA; STROKE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 20444502966     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2005.01.001     Document Type: Article

References (42)

1. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Morbidity and mortality of a multicountry prospective cohort of 1638 patients with polycythemia vera. J Clin Oncol (in press)
2. Gruppo Italiano Policitemia Vera (GISP) Polycythemia Vera: the natural history of 1213 patients followed over 20 years Ann Intern Med 123 1995 656 664
3. T. Barbui, G. Barosi, and A. Grossi Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica 89 2004 215 232
4. A. Tefferi, R. Fonseca, and D. Pereira A long-term retrospective study of young women with essential thrombocythemia Mayo Clin Proc 76 2001 22 28
5. S. Cortelazzo, P. Viero, and G. Finazzi Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia J Clin Oncol 8 1990 556 562
6. P.D. Berk, J.D. Goldberg, P.B. Donovan, S.M. Fruchtman, N.I. Berlin, and L.R. Wasserman Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols Semin Hematol 23 1986 132 143
7. M.L. Randi, G. Luzzatto, and F. Fabris Low-risk thrombocythemia in patients younger than 40 Br J Haematol 104 1999 928 936
8. C. Besses, F. Cervantes, and A. Pereira Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients Leukemia 13 1999 150 154
9. C.N. Harrison, R.E. Gale, and S.J. Machin A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications Blood 93 1999 417 424
10. P. Chiusolo, E.O. La Barbera, and L. Laurenti Clonal hemopoiesis and risk of thrombosis in young females with essential thrombocythemia Exp Hematol 29 2001 670 676
11. L. Teofili, F. Pierconti, and A. Di Febo The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia Blood 100 2002 714 717
12. P. Johansson, A. Ricksten, L. Wennstrom, L. Palmqvist, J. Kutti, and B. Andreasson Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythemia Br J Haematol 123 2003 513 516
13. M. Ruggeri, H. Gisslinger, and A. Tosetto Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia Am J Hematol 71 2002 1 6
14. C.N. Harrison, S. Donohue, and P. Carr Patients with essential thrombocytaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis Thromb Haemost 87 2002 802 807
15. R. Jantunen, E. Juvonen, and E. Ikkala The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia Ann Hematol 80 2001 74 78
16. P.J. van Genderen, and J.J. Michiels Erythromelalgic, thrombotic and hemorrhagic manifestations of thrombocythaemia Presse Med 23 1994 73 77
17. P.J. van Genderen, U. Budde, and J.J. Michiels The reduction of large vonWillebrand multimers in plasma in essential thrombocythemia is related to the platelet count Br J Haematol 93 1996 962 965
18. J.L. Spivak Polycythemia vera: myths, mechanisms and management Blood 100 2002 4272 4290
19. Y. Najean, and J.-D. Rain The very long term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981 Semin Hematol 34 1997 6 16
20. R. Landolfi, R. Marchioli, and J. Kutti Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2004 114 124
21. M. Ruggeri, G. Finazzi, and A. Tosetto No treatment for low-risk essential thrombocythemia: results from a prospective study Br J Haematol 103 1998 772 777
22. S.M. Fruchtman, K. Mack, and M.E. Kaplan From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera Semin Hematol 34 1997 17
23. Y. Najean, J.D. Rain for the French Polycythemia Study Group Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years Blood 90 1997 3370 3377
24. C. Haanen, G. Mathe, and M. Hayat Treatment of polycythemia vera by radiophosphorus or busulphan. A randomizesd clinical trial Br J Cancer 44 1981 75
25. R.T. Silver Interferon alpha2b: a new treatment for polycythemia vera Ann Intern Med 119 1993 1091 1092
26. E. Lengfelder, U. Berger, and R. Hehlmann Interferon alpha in the treatment of polycythemia vera Ann Hematol 79 2000 103 109
27. Silver RT, Fruchtman SM, Feldman EJ, Spivak JL, Salvado AJ. Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. In: Abstract presented at the 46th American Society of Hematology Meeting, San Diego CA, 2004
28. S. Cortelazzo, G. Finazzi, and M. Ruggeri Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial N Engl J Med 332 1995 1132
29. Y. Sterkers, C. Preudhomme, and J.-L. Lai Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion Blood 91 1998 616 622
30. S. Nand, W. Stock, and J. Godwin Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis Am J Hematol 52 1996 42 46
31. G. Finazzi, M. Ruggeri, F. Rodeghiero, and T. Barbui Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis Blood 101 2003 3749
32. G. Finazzi, M. Ruggeri, F. Rodeghiero, and T. Barbui Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial Br J Haematol 110 2000 577 583
33. S. Murphy, H. Iland, and D. Rosenthal Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group Semin Hematol 23 1986 177
34. S.M. Fruchtman, R.M. Petitt, and H.S. Gilbert Anagrelide: analysis of long term safety and leukemogenic potential in myeloproliferative diseases Blood 100 2002 70a
35. E.C. Storen, and A. Tefferi Long-term use of anagrelide in young patients with essential thrombocythemia Blood 97 2001 863 866
36. Green A, Campbell P, Buck G, et al. The Medical Research Council PT1 trial in essential thrombocythemia. In: Abstract Presented at the 46th American Society of Hematology Meeting, San Diego CA, 2004
37. E. Lengfelder, M. Griesshammer, and R. Hehlmann Interferon-alpha in the treatment of essential thrombocythemia Leuk Lymphoma 22 suppl.1 1996 135 142
38. P. Bernasconi, M. Boni, and P.M. Cavigliano Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosomal abnormalities in patients treated with pipobroman or hydroxyurea Leukemia 16 2002 2078 2083
39. T.C. Liu, and R. Suri Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndromes Blood 92 1998 1465 1466
40. V.N. Hanft, S.R. Fruchtman, and C.V. Pickens Acquired DNA mutations associated with in vivo hydroxyurea exposure Blood 95 2000 3589 3593
41. K. Shibata, Y. Shimamoto, and K. Suga Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - a brief review of recent literature Acta Haematol 91 1994 84 88
42. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study. Blood 2004;Dec 7:[Epub ahead of print]